☆ 4.7 Article

Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials

DIABETES OBESITY & METABOLISM (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cardiac & Cardiovascular Systems

Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial

Kelley R. H. Branch et al.

Summary: The study found that the use of dulaglutide, a glucagon-like peptide 1 agonist, did not reduce the incidence of heart failure events in patients with type 2 diabetes, regardless of their baseline heart failure status, over a period of 5.4 years.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes

Joao Pedro Ferreira et al.

Summary: The GLP1-RA albiglutide appears to have limited effect on reducing HF-related events among patients with a history of heart failure.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

Hertzel C. Gerstein et al.

Summary: The trial compared the cardiovascular and renal outcomes of weekly injections of efpeglenatide versus a placebo in participants with type 2 diabetes and a history of cardiovascular disease or current kidney disease. The study found that the risk of cardiovascular events was lower with efpeglenatide treatment, and a composite renal outcome event was also reduced.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Mansoor Husain et al.

DIABETES OBESITY & METABOLISM (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure

Steven P. Marso et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Will long-acting glucagon-like peptide-1 analogues recapitulate our agonizing experience with cyclic AMP-dependent positive inotropic agents in heart failure?

Milton Packer

EUROPEAN JOURNAL OF HEART FAILURE (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Anders Jorsal et al.

EUROPEAN JOURNAL OF HEART FAILURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Rury R. Holman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial

Kenneth B. Margulies et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)

添加到收藏夹

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

添加到收藏夹

Article Medicine, General & Internal

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program

Ali Vazir et al.

EUROPEAN HEART JOURNAL (2015)

添加到收藏夹

Article Mathematical & Computational Biology

Quantifying heterogeneity in a meta-analysis

JPT Higgins et al.

STATISTICS IN MEDICINE (2002)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A

CL Antos et al.

CIRCULATION RESEARCH (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.